PXG golf clubs have been on the market for over a decade, offering uber-premium golf equipment to many different player categories, specifically avid and better players. But the brand has never ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

What you should know: The PXG Wildcat package is a nine-club set designed for people who are new to golf. It blends technologies found in PXG’s premium clubs into a high-lofted driver ...

Looking to learn what you need to know about the latest new products from PXG? These handy thumbnails will keep you up to date on the company's new releases across all club and ball catetgories.

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...